The causes, diagnosis, and treatment of recurrent ovarian cancer. A literature review and analysis of the authors’ data

Новикова, Е. Г.; Moskovskaya, E. Yu .

doi:10.17116/onkolog20154359-67

Onkol. Z. im. P.A. Gercena

2015

DOI: 10.17116/onkolog20154359-67

|View full text |Cite

The causes, diagnosis, and treatment of recurrent ovarian cancer. A literature review and analysis of the authors’ data

Е. Г. Новикова¹,

E. Yu . Moskovskaya²

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2020

2023

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Bevacizumab in maintenance therapy for ovarian cancer patients

Владимирова

Эдуардовна

Александровна

et al. 2020

jour

View full text Add to dashboard Cite

Ovarian cancer is one of the most common cancers in women. Growth and extension of the tumor are associated with active neoangiogenesis regulated by vascular endothelial growth factor (VEGF). Bevacizumab decreases VEGF activity and inhibits the tumor growth.Purpose of the study. The aim of the study was to evaluate results of bevacizumab in maintenance therapy for ovarian cancer.Materials and methods. 26 patients with ovarian cancer received maintenance therapy with drop infusions of bevacizumab 15 mg/kg once a day for 21 days in 2014–2019 after completing chemotherapy for relapses.Results. Bevacizumab mainterned partial response or stabilization in 76.9% of patients. The adverse events were mainly of grades 1–2 (in 88.5% of all adverse events) and could be managed by an appropriate medical correction. Hemorrhagic complications caused the cancellation of bevacizumab in one patient.Conclusions. Bevacizumab in maintenance therapy after completing chemotherapy for ovarian cancer relapses (both platinum-sensitive and platinum-resistant) significantly improves the treatment results. The toxicity profile of bevacizumab in maintenance treatment is acceptable.

show abstract

Bevacizumab in maintenance therapy for ovarian cancer patients

Владимирова

Эдуардовна

Александровна

et al. 2020

jour

View full text Add to dashboard Cite

show abstract

Рецидивы Рака Яичников, Классификация, Общие Принципы Лечения

Арутюнян¹,

Джилавян²

2023

Medical Science of Armenia

View full text Add to dashboard Cite

A review of the literature on modern approaches to the drug treatment of recurrent ovarian cancer is presented. The general principles of classification and treatment of ovarian cancer relapses are analyzed. The existing points of view regarding the beginning of fixing the progression of the disease, the optimal timing of the start of treatment are given. Ներկայացված է գրականության ակնարկ ձվարանների կրկնվող քաղցկեղի դեղորայքային բուժման ժամանակակից մոտեցումների վերաբերյալ: Վերլուծվում են ձվարանների քաղցկեղի ռեցիդիվների դասակարգման և բուժման ընդհանուր սկզբունքները: Տրված են առկա տեսակետները հիվանդության առաջընթացի ֆիքսման սկզբի, բուժման մեկնարկի օպտիմալ ժամկետների վերաբերյալ:

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

The causes, diagnosis, and treatment of recurrent ovarian cancer. A literature review and analysis of the authors’ data

Cited by 2 publications

References 33 publications

Bevacizumab in maintenance therapy for ovarian cancer patients

Bevacizumab in maintenance therapy for ovarian cancer patients

Рецидивы Рака Яичников, Классификация, Общие Принципы Лечения

Contact Info

Product

Resources

About